In its annual report, issued earlier this week, the Medicare program’s trustees said that Medicare will remain solvent until 2029, allowing the program to forestall triggering an Affordable Care Act provision to convene the Independent Payment Advisory Board.
In its annual report, issued earlier this week, the Medicare program’s trustees said that Medicare will remain solvent until 2029, allowing the program to forestall triggering an Affordable Care Act (ACA) provision to convene the Independent Payment Advisory Board (IPAB).
The IPAB, a 15-member panel (or the HHS if such a panel cannot be convened), will be called upon when Medicare spending exceeds statutory benchmarks. The body will be required to provide recommendations to Congress on mandatory cost-cutting measures to control Medicare spending.
The IPAB provision of the ACA has been widely criticized by stakeholders, including the American Medical Association (AMA), which has advocated for a repeal of the provision. The AMA calls IPAB an “inflexible mandate to impose arbitrary across-the-board cuts to physicians and other providers that could adversely affect access to health care services for Medicare patients.” Pharmaceutical industry trade group PhRMA echoed the AMA’s views, saying that proposals made by IPAB would be “…likely to restrict patients’ access to needed health care services and treatments by disproportionately targeting new treatments as a way to cut spending—prioritizing cost-cutting ahead of a medicine’s benefits to patients.”
The announcement that the IPAB would not be formed this year came welcome news to the biotechnology industry, which was bracing for the board’s implementation. The 2016 report from the same body projected that 2017 spending levels would trigger the IPAB provision this summer, and many in the industry feared that IPAB’s primary recommendations to reduce Medicare costs would target expensive biologic treatments, forcing biopharmaceutical companies to make substantial price concessions on their products.
Despite broad industry criticism of IPAB, a growing bipartisan push in the House and Senate to repeal the deeply unpopular provision, and Republicans’ promises to repeal and replace the ACA, Senate healthcare reform legislation leaves the IPAB provision untouched. According to the original legislation’s language, Congress would have to pass a joint resolution to repeal the IPAB provision before August 15 of this year. Such a resolution would have to be passed by a three-fifth’s majority in both chambers, and that is an unlikely scenario as Senate Majority Leader Mitch McConnell (R-Kentucky) focuses on gaining enough votes to pass the latest version of the healthcare reform bill.
Even though IPAB will not be be enforcing mandatory cost controls on Medicaid, other deep cuts are on the way. The Centers for Medicare and Medicaid Services (CMS) has proposed a rule, due to be published in the Federal Register on July 20, that would revise the Medicare hospital outpatient prospective payment system and the Medicare ambulatory surgical center payment system for 2018.
The rule would cut the applicable payment rate for separately payable drugs and biologics acquired under the 340B program from the average sales price (ASP) plus 6% to the ASP minus 22.5%. These cuts are part of a CMS effort to curb the growth of spending, which CMS says grew faster among hospitals that participated in the 340B program than among hospitals that did not, noting that Medicare beneficiaries at 340B hospitals were either prescribed more drugs or were prescribed more expensive drugs than were beneficiaries in other hospitals.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.